A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results

por Eisen, T, Loembé, A-B, Shparyk, Y, MacLeod, N, Jones, R J, Mazurkiewicz, M, Temple, G, Dressler, H, Bondarenko, I
Publicado 2015